anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The aim of this study was to investigate postoperative imaging findings of patients who underwent breast-conserving surgery for cancer and reconstruction with MegaDerm® (sheet-type and pellet-type), analyzing false positives and recurrences, using multi-modality images.
MATERIALS AND METHODS: This study included 201 women (age range: 28-81 years, mean age ± standard deviation: 53.2 ± 8.6 years) who underwent breast-conserving surgery and immediate reconstruction with MegaDerm®. Post-surgery, each patient underwent at least one mammography (MG), ultrasonography (US), and MRI, totaling 713 MG, 1063 US, and 607 MRI examinations. Postoperative images were reviewed separately for the two types of MegaDerm®, and suspicious imaging findings (false positives and recurrences) were analyzed, with a particular focus on the findings in direct contact with MegaDerm®.
RESULTS: MegaDerm® appeared as a circumscribed mass with homogeneous iso- or high density on MG, posterior shadowing on US, and no enhancement on MRI. Calcification was more common and increased in size in sheet-type MegaDerm®, while pellet-type often exhibited irregular margins. Nine out of 17 false positives had suspicious findings in direct contact with MegaDerm®, and six out of nine recurrences showed similar findings. Common suspicious findings included calcifications, asymmetries, and MegaDerm® irregularities on MG; masses and MegaDerm® irregularities on US; and enhancing masses and MegaDerm® irregularities with enhancement on MRI. Notably, MegaDerm® irregularity with calcification was observed on MG and US in only one recurrence case. In 44.4% (4/9) of false-positives in direct contact with MegaDerm®, suspicious findings showed no change or resolution on follow-up.
CONCLUSION: Suspicious imaging findings in direct contact with MegaDerm® may be associated with false positives or recurrences. Therefore, it is essential to recognize these characteristic findings and review the patient's history of MegaDerm® insertion when in doubt.
Ultrasound-guided bilateral TAP block (in-plane technique) will be performed in this group. Levobupivacaine 0.25 % 20 ml + dexmedetomidine 0,5 μg/kg will be administered in the block on each side.
NEW MATERIAL:A physiologically active substance MBP049-13 expressed by the formula. USE:With inhibitory activity against proline hydroxylase, useful as a remedy for fibrosis such as cirrhosis or pulmonary fibrosis and having great effects at a low concentration. PREPARATION:A microorganism, belonging to the genus Ophiobolus and capable of producing the physiologically active substance MBP049-13 is cultured and the objective substance is collected from the resultant culture and obtained. For example, Ophiobolus.rubellus MCI2552 strain (FERM P-11575), newly separat ed from vegetational plant bodies and belonging to a fungus of the class Loculoascomycetes is cited as the microorganism having the ability to produce the physiologically active substance MBP049-13. The aforementioned microorgan ism is cultured in a culture medium containing nutriments utilizable by normal microorganisms. A culture method under aerobic conditions is suitable for the culture method. The culturing temperature is preferably about 26-30 deg.C.
The chemokine CXCL12 (also called SDF-1 - stromal-derived-factor-1) and its receptor, CXCR4 ((CXC Chemokine Receptor 4), a molecule endowed with potent chemotactic activity for hematopoietic cells, together play a pivotal role in the trafficking of hematopoietic stem cells to the bone marrow 10,11. The CXCL12/CXCR4 axis is also critically involved in the retention of hematopoietic cells within the BM microenvironment. Following chemotherapy and irradiation, the CXCL12/CXCR4 axis delays the recovery of the BM progenitor cells and the exit of mature cells such as neutrophils and monocytes to the periphery. Consequently, disruption of the CXCL12/CXCR4 interaction results in mobilization of hematopoietic cells including stem cells and a faster recovery of the treated BM.

BKT140 (4F-benzoyl-TN14003) is a highly selective and unique CXCR4 antagonist. Pre-clinical studies showed that BKT140 binds CXCR4 with high affinity (1nM) 13. Biokine has demonstrated the ability of the CXCR4 antagonist, BKT140, to mobilize various WBC such as neutrophils and monocytes as well as progenitor and stem cells, from the BM. The ability of BKT140 to stimulate the mobilization of these cells is superior to that of AMD3100, a CXCR4 antagonist that is in clinical development for mobilization of stem cells in MM and lymphoma patients, both qualitatively and quantitatively. BKT140 synergizes much more efficiently with G-CSF when compared to AMD3100. Moreover, Biokine has shown that BKT140, in synergism with G-CSF (NEUPOGEN®), is much more efficient in increasing the numbers of neutrophils and activated monocytes in the blood, by several folds as compared to G-CSF alone. BKT140 also shortens the neutropenic period due to an early release of neutrophils and monocytes from the BM. More importantly, BKT140, in synergism with G-CSF, reduces the anemic period caused by chemotherapy, due to a RBC production, which does not occur when G-CSF is given as a sole treatment. More importantly, BKT140, but not G-CSF or AMD3100, is also capable of shortening the period of cytopenia by boosting both the recovery of all hematopoietic cells in the BM and their exit to the periphery, and therefore shortening the period of cytopenia following chemotherapy or irradiation and BM transplantation. Importantly, Biokine has shown that upon interaction with CXCR4, BKT140, but not AMD3100, selectively, specifically and rapidly stimulates human leukemia and myeloma cell death in vitro and in vivo. Furthermore, BKT140 synergizes with other chemotherapeutic agents such as rapamycine to induce MM cell death.
Participants will receive amivantamab in combination with docetaxel in 2 cohorts (Cohort A \[adenocarcinoma\] and Cohort B \[squamous\]) at the RP2CD determined in Phase 1. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.
Terbutaline sulfate USP, the active ingredient of terbutaline sulfate injection, is a beta-adrenergic agonist bronchodilator available as a sterile, nonpyrogenic, aqueous solution in vials, for subcutaneous administration. Each milliliter of solution contains 1 mg of terbutaline sulfate USP (0.82 mg of the free base), sodium chloride for isotonicity, and hydrochloric acid for adjustment to a target pH of 4. Terbutaline sulfate is (±)-α-[(tert-butylamino)methyl]-3,5-dihydroxybenzyl alcohol sulfate (2:1) (salt). The molecular formula is (C12H19N03)2•H2SO4 and the structural formula is:

Terbutaline sulfate USP is a white to gray-white crystalline powder. It is odorless or has a faint odor of acetic acid. It is soluble in water and in 0.1N hydrochloric acid, slightly soluble in methanol, and insoluble in chloroform. Its molecular weight is 548.65.
A healthcare-monitoring system collects health data through sensors then analyzes the data. The system may then instruct the user to retrieve one or more medical devices or tests stored within the system and perform an additional diagnostic measurement or test. Medication may also be stored within the system. The location of a medical device, test, or medication may be tracked in relation to the position of the user and the user's body parts. Correct use of the medical device or test and consumption of the medication may be assessed. A user interface may provide instruction for proper use of a medical device or test as well as its location within the system. Sensors may indicate whether a medical device has been returned to its proper place or if a consumable medical product has been removed from storage. The system may automatically reorder consumable medical supplies and track drug compliance.
Participants will be randomly assigned to one of three intervention arms. Two brief stimulation periods will be conducted on day one. One brief stimulation will be scheduled in the morning and a second brief stimulation will be scheduled in the afternoon. A final stimulation will be conducted on day two. Direct Current Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
Alzheimer's disease (AD) is a global concern. Due to the lack of effective therapeutic methods targeting late-stage AD patients, it is critical to investigate brain alterations in the preclinical stage to pave the way for early diagnosis and intervention. Structural and functional magnetic resonance imaging (MRI) has been proven to be an effective and non-invasive approach to explore the neural mechanisms underlying neurological disorders. Genetic factors such as apolipoprotein E and plasma biomarkers play important roles in AD development and progression. However, the interaction effects of risk genes and different pathologic pathways implicated in the pathogenesis of AD remain unclear. Furthermore, the diagnostic and prognostic models that could predict future cognitive decline or clinical progression based on objective features derived from baseline demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma data need to be further explored.

We aim to investigate the neural basis underlying early cognitive deficits using structural and functional MRI data combined with novel analytical methods such as dynamic functional connectivity, surface-based morphometry, graph theory, multilayer network, functional-structural coupling, hidden Markov model, and connectome gradient mapping. Secondly, to explore the interaction effects of risk genes, which may help a better illustration of different biological pathways implicated in the pathogenesis of Alzheimer's disease. Thirdly, to investigate the divergent and dynamic abnormalities of multimodal imaging markers across different stages of Alzheimer's disease and their associations with plasma biomarkers, which may enhance our understanding of the neuropathological mechanisms. Fourthly, to provide scientific evidence on the potential targets for early intervention of neurodegenerative diseases. Lastly, to establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline multimodal biomarkers. These studies may help a better understanding of the neural and biological basis underlying AD and pave the way for early diagnosis and intervention.
PURPOSE: To obtain the subject agent containing a specific vitamin D derivative as an active ingredient and capable of specifically suppressing proliferation of fibroneuroma cell. CONSTITUTION: This treating agent contains a compound of formula I [R<1> and R<2> are each a 1-4C alkyl; A is O or S; (n) is 2 or 3] as an active ingredient. The compound of formula I includes e.g. 1α,3β-dihydroxy-20(R)-(4-hydroxy-4- methylpentylthio)-9,10-secopregna-5,7,10(19)-triene. The compound of formula I is obtained by successively carrying out deprotection and acylation of a compound of formula II, reacting the reactional product with thiol of formula III obtained from a halogenated ester, and deprotecting the reactional product. Furthermore, the agent is preferably systemically administered as an oral medicine or injection. The dose of the compound of formula I is preferably 1-20μm/ person.
FIELD: medicine. SUBSTANCE: method involves carrying out single lung ventilation when isolating the second one after both lungs ventilation being done during 15 min in advance. Normal gas exchange parameters being achieved, lung with no ventilation is subjected to lavage with liquid. The first portion to be poured is 2100-3000 ml as large and the following ones are 400-800 ml as large. The number of lavage cycles is 5-7 pro one lung. To prevent from hydratation and pulmonary edema to take place, diuresis is to be stimulated. Intravenous infusion volume is reduced for the same purposes. 5% glucose solution is applied. EFFECT: enhanced effectiveness of treatment; optimum lavage mode with low risk of complications. 4 cl, 1 dwg, 6 tbl
Methods of inhibiting the proliferation of colorectal, gastric and esophageal cancer cells in an individual are disclosed. The methods comprise administering to an individual a sufficient amount of ST receptor ligand in a manner such that the proliferation of such cells is inhibited. Enhanced methods of treating an individual who has metastasized colorectal or primary or metastatic gastric or esophageal cancer are disclosed. Methods of increasing the number of ST receptor molecules on the surface of a colorectal cell in an individual are disclosed. The methods comprise administering to an individual an ST receptor ligand in a manner such that the ST receptor ligand comes into contact with an ST receptor on the surface of the colorectal cell in the individual. Methods of increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell in an individual who has metastasized colorectal cancer are disclosed. The methods comprise the step of administering to the individual an ST receptor ligand. Pharmaceutical compositions that comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent are disclosed. Methods of treating an individual who has metastasized colorectal cancer are disclosed. The methods comprise the steps of increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell in the individual and then administering a therapeutic pharmaceutical composition that comprises components which target ST receptor for delivery of a therapeutic agent to the individual. Methods of imaging a metastasized colorectal tumor in an individual who has metastasized colorectal cancer are disclosed. The methods comprise the steps of increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell in the individual and then administering an pharmaceutical imaging composition that comprises components which target ST receptor for delivery of an imaging agent. Methods of determining whether an individual has metastasized colorectal cancer are disclosed. Methods of delivering an active compound to a colorectal cell in an individual are disclosed.
In this study, we aimed to discover novel GLP-1 analogues from natural sources. We investigated GLP-1 analogues from fish and amphibians, and bullfrog GLP-1 (bGLP-1) showed the highest potency. Starting with bGLP-1, we explored the structure-activity relationship and performed optimization and long-acting modifications, resulting in a potent analogue called 2f. Notably, 2f exhibited superior effects on food intake, glycemic control, and body weight compared to semaglutide. Furthermore, we explored the usefulness of bGLP-1 in designing GLP-1-based multiagonists. Using the bGLP-1 sequence, we designed novel dual GLP-1/glucagon receptor agonists and triple GLP-1/GIP/glucagon receptor agonists. The selected dual GLP-1/glucagon receptor agonist 3o and triple GLP-1/GIP/glucagon receptor agonist 4b exhibited significant therapeutic effects on lipid regulation, glycemic control, and body weight. Overall, our study highlights the potential of discovering potent GLP-1 receptor agonists from natural sources. Additionally, utilizing natural GLP-1 analogues for designing multiagonists presents a practical approach for developing antiobesity and antidiabetic agents.
Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Health literacy is a critically important skill that helps people to become active participants in their health care. The 2003 National Assessment of Adult Literacy showed that more than 75 million Americans had basic health literacy skills, indicating that as many as 1 in 4 Americans can have difficulty understanding information about their healthcare. Persons in racial and ethnic minorities are likely to have even lower levels of health literacy. Twenty-four percent of blacks (9.5 million persons) and 41% of Hispanics (21 million persons) have below basic levels of health literacy. These persons have lower levels of health literacy and compelling evidence, including our own findings (see below), link race and ethnicity to disparities in health via health literacy. Members of minority groups and older adults are more frequently affected by chronic diseases such as cancer, high blood pressure, heart attack, stroke, diabetes, elevated cholesterol, asthma, hepatitis C, HIV infection, mental health disorders and many others. The twin burdens of chronic disease and low levels of health literacy thus fall disproportionately on those most in need - members of minorities and older adults, all of whom likely to experience one or more chronic conditions while often not having the health literacy skills to help them cope.

Chronic disease self-management (CDSM) is a logical target for a general health literacy intervention. In an approach that cuts across specific diseases. CDSM targets problems and skills needed to cope with issues such as fatigue, pain, stress, depression, sleep disturbance and treatment adherence. Studies show that in-person CDSM classes improve patients' functioning and reduce healthcare utilization, but their availability is limited due to the lack of qualified personnel and cost. Similarly, while interventions have been developed to improve health literacy, they are difficult to scale to levels needed to meet the challenge of low health literacy (for more than 40 million persons) due to their cost. Effective interventions with the potential for wider dissemination at reasonable costs are urgently needed.

In a previous study, the investigators showed that a computer-delivered tailored information intervention targeting health literacy that can deployed either as an information kiosk in a clinical office or on the Internet could be cost-effective in improving patients' health literacy and adherence. It is not clear, however, whether the same sort of computer-delivered, multimedia and interactive approach will be effective in improving CDSM skills in persons with low baseline levels of health literacy, and if it is, whether its effects will extend beyond health literacy to general health, self-efficacy, activation, and treatment adherence. In this follow-up study the investigators will evaluate this possibility by creating a personally relevant computer-delivered intervention targeting CDSM and health literacy among African-Americans, Hispanics, and white non-Hispanics:
OBJECTIVES: This work investigated the acute antinociceptive effect of a synthetic chalcone, 4-dimethylamino chalcone (DMAC), as well as its effects on vincristine-induced peripheral neuropathy (VIPN) in mice.
METHODS: The inhibitory activity of myeloperoxidase was assessed by measuring HOCl formation. Formalin and hot plate tests were used to study the acute antinociceptive effect of DMAC. VIPN was induced through the administration of vincristine sulphate (0.1 mg/kg, i.p., 14 days). Then, DMSO, DMAC (10 or 30 mg/kg; i.p.), or pregabalin (10 mg/kg, i.p.) were administered for 14 consecutive days. Thermal hyperalgesia and mechanical allodynia were evaluated before and after VIPN induction and on days 1, 3, 7, and 14 of treatment. Neurodegeneration and neuroinflammation were assessed through immunohistochemistry for NF200, iNOS, and arginase-1 within the sciatic nerve.
KEY FINDINGS: DMAC inhibited myeloperoxidase activity in vitro and presented an acute antinociceptive effect in both formalin and hot plate tests, with the involvement of muscarinic and opioid receptors. Treatment with 30 mg/kg of DMAC significantly attenuated thermal hyperalgesia and mechanical allodynia and prevented macrophage proinflammatory polarisation in VIPN mice.
CONCLUSIONS: Our results show that DMAC, acting through different mechanisms, effectively attenuates VIPN.
The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention.
1300571 Polyacrylic acid/metal oxide surgical cements NATIONAL RESEARCH DEVELOPMENT CORP 8 May 1970 [16 May 1969] 25020/69 Addition to 1139430 Headings C3N and C3P A surgical cement similar to that disclosed in Specification 1,139,430 (N.R.D.C.) which hardens after remaining plastic for sufficient time for it to be formed into a desired shape, comprises a mixture of a surgically acceptable grade of metal oxide powder, a water soluble polymer of acrylic acid having a viscosity determined molecular weight of 5000 to 250,000, and water, the weight of acrylic acid polymer being from 20 to 60% of the combined weight of acrylic acid polymer and water, and the ratio by weight of the metal oxide powder to water and polymer, being from 0À5 : 1 to 4 : 1. Anything disclosed or claimed in the main patent, 1,139,430, is disclaimed. The preferred polymer is polyacrylic acid and the preferred metal oxide is ZnO, although others specified are MgO (Example 1), BiO, CdO, HgO, CaO, CuO, SrO, BaO and AgO. A mixture, e.g. of ZnO and MgO (Example 4) may also be used. Preferably the polymer is dissolved in water, prior to the addition of the metal oxide. The composition may take the form of a two component pack, one pack containing the polymer solution, and the other containing the metal oxide. The compositions are especially applicable to dentistry. In examples polymers of acrylic acid are made by polymerizing acrylic acid in water containing isopropanol, with an initiator of ammonium persulphate.